On Public Health and New Prostate Cancer Screening Strategies
Comparison of Methods and Results for Prevention
DOI:
https://doi.org/10.56226/97Keywords:
Prostate Cancer, Prostate-Specific Antigen, PCa Diagnosis, PCa Screening, Public HealthAbstract
Introduction: Prostate cancer (PCa) is one of the leading causes of death among men worldwide. Early detection is crucial for effective treatment, and several screening strategies have been developed to improve diagnostic accuracy and reduce false positives. This study compares new prostate cancer screening strategies, assessing their effectiveness, accuracy, cost-effectiveness and impact on patients' quality of life. Methodology: This comparative observational study analyzed clinical data from men aged 50 to 75 years without a previous diagnosis of prostate cancer. A literature search was conducted to determine advances in diagnosis and treatment efficacy. Results: The results showed that the combination of PSA and multiparametric MRI increased diagnostic accuracy and reduced false positives. Liquid biopsy was a promising, less invasive tool with potential for early detection. In terms of cost-benefit, the multimodal approach proved to be advantageous, considering the costs of subsequent examinations and treatments, as well as the impacts on patients' quality of life. Conclusion: New prostate cancer screening strategies have distinct advantages and limitations. Combining methods significantly improves clinical outcomes, reducing mortality and promoting a better quality of life for patients. This study highlights the importance of a multimodal approach to prostate cancer screening and the need for continued research to validate these strategies in different populations and clinical settings.
References
Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., Li, H., & Lu-Yao, G. L. (2011). Impact of comorbidity on survival among men with localized prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(10), 1335–1341. https://doi.org/10.1200/JCO.2010.31.2330
Borson, S., Scanlan, J. M., Chen, P., & Ganguli, M. (2003). The Mini-Cog as a screen for dementia: validation in a population-based sample. Journal of the American Geriatrics Society, 51(10), 1451–1454. https://doi.org/10.1046/j.1532-5415.2003.51465.x
Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (Eds.). (2017). TNM classification of malignant tumours. John Wiley & Sons.
Ceci, F., Oprea-Lager, D. E., Emmett, L., Adam, J. A., Bomanji, J., Czernin, J., Eiber, M., Haberkorn, U., Hofman, M. S., Hope, T. A., Kumar, R., Rowe, S. P., Schwarzenboeck, S. M., Fanti, S., & Herrmann, K. (2021). E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European journal of nuclear medicine and molecular imaging, 48(5), 1626–1638. https://doi.org/10.1007/s00259-021-05245-y
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012). International variation in prostate cancer incidence and mortality rates. European urology, 61(6), 1079–1092. https://doi.org/10.1016/j.eururo.2012.02.054
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., Humphrey, P. A., & Grading Committee (2016). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. The American journal of surgical pathology, 40(2), 244–252. https://doi.org/10.1097/PAS.0000000000000530
Gnanapragasam, V. J., Lophatananon, A., Wright, K. A., Muir, K. R., Gavin, A., & Greenberg, D. C. (2016). Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. PLoS medicine, 13(8), e1002063. https://doi.org/10.1371/journal.pmed.1002063
Gnanapragasam, V. J., Bratt, O., Muir, K., Lee, L. S., Huang, H. H., Stattin, P., & Lophatananon, A. (2018). The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC medicine, 16(1), 31. https://doi.org/10.1186/s12916-018-1019-5
Golla, V., & Kaplan, AL (2017). Terapia com testosterona em vigilância ativa e após tratamento definitivo para câncer de próstata. Current urology reports , 18 , 1-7.
Haider, A., Zitzmann, M., Doros, G., Isbarn, H., Hammerer, P., & Yassin, A. (2015). Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. The Journal of urology, 193(1), 80–86. https://doi.org/10.1016/j.juro.2014.06.071
Han, H. H., Park, J. W., Na, J. C., Chung, B. H., Kim, C. S., & Ko, W. J. (2015). Epidemiology of prostate cancer in South Korea. Prostate international, 3(3), 99–102. https://doi.org/10.1016/j.prnil.2015.06.003
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., Wong, L. M., Taubman, K., Ting Lee, S., Hsiao, E., Roach, P., Nottage, M., Kirkwood, I., Hayne, D., Link, E., Marusic, P., … proPSMA Study Group Collaborators (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet (London, England), 395(10231), 1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7
Hugosson, J., Godtman, R. A., Carlsson, S. V., Aus, G., Grenabo Bergdahl, A., Lodding, P., Pihl, C. G., Stranne, J., Holmberg, E., & Lilja, H. (2018). Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scandinavian journal of urology, 52(1), 27–37. https://doi.org/10.1080/21681805.2017.1411392
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., Lilja, H., Denis, L. J., Recker, F., Paez, A., Puliti, D., Villers, A., Rebillard, X., Kilpeläinen, T. P., Stenman, U. H., Godtman, R. A., … ERSPC investigators (2019). A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European urology, 76(1), 43–51. https://doi.org/10.1016/j.eururo.2019.02.009
Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ (Clinical research ed.), 362, k3519. https://doi.org/10.1136/bmj.k3519
Kimura, T., & Egawa, S. (2018). Epidemiology of prostate cancer in Asian countries. International journal of urology : official journal of the Japanese Urological Association, 25(6), 524–531. https://doi.org/10.1111/iju.13593
Migowski, A., & Silva, G. A. e .. (2010). Sobrevida e fatores prognósticos de pacientes com câncer de próstata clinicamente localizado. Revista De Saúde Pública, 44(2), 344–352. https://doi.org/10.1590/S0034-89102010000200016
Lloyd Williams, D. (2022). On Healthcare Research Priorities in the USA : From Long COVID to Precision Health, what else is new?. International Healthcare Review (online), 1(1). https://doi.org/10.56226/ihr.v1i1.14
Maluf, G., Vianna, A., Kenupp, M. G., & Uyeda, M. (2024). Clinical pathological features and radiotherapy treatment for adenoid cystic carcinoma of the head and neck: An Update on recent evidence. International Healthcare Review (online). https://doi.org/10.56226/79
Noujeim, JP, Belahsen, Y., Lefebvre, Y., Lemort, M., Deforche, M., Sirtaine, N., ... & Diamand, R. (2023). Otimizando a biópsia direcionada à ressonância magnética multiparamétrica e a detecção de câncer de próstata clinicamente significativo: o papel da amostragem perilesional. Câncer de próstata e doenças prostáticas , 26 (3), 575-580.
Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., & Murphy, D. G. (2020). Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European urology, 77(4), 403–417. https://doi.org/10.1016/j.eururo.2019.01.049
Kenupp, M. G., Vianna, A., Uyeda, M., & Maluf, G. (2024). On Patients with Colorectal Cancer : Associations, prognosis, survival and effects of therapy performed in the intestinal microbiota. International Healthcare Review (online). https://doi.org/10.56226/83
Maluf, G., Vianna, A., Kenupp, M. G., & Uyeda, M. (2024). Clinical pathological features and radiotherapy treatment for adenoid cystic carcinoma of the head and neck: An Update on recent evidence. International Healthcare Review (online). https://doi.org/10.56226/79
Ploussard, G., Manceau, C., Beauval, JB, Lesourd, M., Almeras, C., Gautier, JR, ... & Roumiguié, M. (2020). Precisão diminuída da classificação do grupo de risco EAU para câncer de próstata na era do caminho diagnóstico guiado por imagem: proposta para uma nova classificação baseada em biópsias direcionadas à ressonância magnética e resultados oncológicos precoces após cirurgia. World Journal of Urology , 38 , 2493-2500.
Sakamoto S. (2018). Editorial Comment to Epidemiology of prostate cancer in Asian countries. International journal of urology : official journal of the Japanese Urological Association, 25(6), 531–532. https://doi.org/10.1111/iju.13707
Schoots, I. G., & Padhani, A. R. (2021). Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU international, 127(2), 175–178. https://doi.org/10.1111/bju.15277
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442
Soeterik, T. F. W., van Melick, H. H. E., Dijksman, L. M., Biesma, D. H., Witjes, J. A., & van Basten, J. A. (2021). Multiparametric Magnetic Resonance Imaging Should Be Preferred Over Digital Rectal Examination for Prostate Cancer Local Staging and Disease Risk Classification. Urology, 147, 205–212. https://doi.org/10.1016/j.urology.2020.08.089
Song, C., & Xie, H. (2023). On Disparities in Breast Cancer Screening: An Analysis of Behavioral Risk Factor Surveillance Survey Data related to Racial/ Ethnic characteristics. International Healthcare Review (online). https://doi.org/10.56226/53
van der Leest, M., Cornel, E., Israel, B., Hendriks, R., Padhani, AR, Hoogenboom, M., ... & Barentsz, JO (2019). Comparação direta de biópsia de próstata guiada por ultrassom transretal versus ressonância de próstata multiparamétrica com biópsia guiada por ressonância magnética subsequente em homens não submetidos a biópsia com antígeno prostático específico elevado: um grande estudo clínico multicêntrico prospectivo. Urologia europeia , 75 (4), 570-578.
van der Kwast, T. H., Amin, M. B., Billis, A., Epstein, J. I., Griffiths, D., Humphrey, P. A., Montironi, R., Wheeler, T. M., Srigley, J. R., Egevad, L., Delahunt, B., & ISUP Prostate Cancer Group (2011). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 24(1), 16–25. https://doi.org/10.1038/modpathol.2010.156
Ye, D., & Zhu, Y. (2015). Zhonghua wai ke za zhi [Chinese journal of surgery], 53(4), 249–252.
Uyeda, M. (2022). On a Global Agenda for Oncology Research: From Biomarker studies to post-genomic technologies. International Healthcare Review (online), 1(1). https://doi.org/10.56226/ihr.v1i1.9
Zhang, L., Liu, X., Xia, R., Chen, F., Wang, X., Bao, J., Shao, Y., Lu, X., Wang, Y., Wang, J., Tun, M. T., Melamed, J., Lepor, H., Deng, F. M., Wang, D., & Ren, G. (2022). Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations. Pathology, research and practice, 234, 153933. https://doi.org/10.1016/j.prp.2022.153933
Zijiu, C., Li, W., & Qin, J. (2025). Philosophical Reflections on Chinese Naturopathy against Malignant Tumours. International Healthcare Review (online). https://doi.org/10.56226/99
Downloads
Published
How to Cite
License
Copyright (c) 2025 The Publisher
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Start-up >